Page last updated: 2024-12-05

zomepirac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

zomepirac: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5733
CHEMBL ID19490
CHEBI ID35859
SCHEMBL ID25735
MeSH IDM0074328

Synonyms (73)

Synonym
33369-31-2
zomepirac
[5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrol-2-yl]acetic acid
CHEBI:35859 ,
5-(4-chlorobenzoyl)-1,4-dimethyl-1h-pyrrole-2-acetic acid
BRD-K81326768-001-02-4
BRD-K81326768-236-03-4
DIVK1C_000953
KBIO1_000953
{5-[(4-chlorophenyl)carbonyl]-1,4-dimethyl-1h-pyrrol-2-yl}acetic acid
SPECTRUM_000306
zomepirac sodium
BSPBIO_002038
PRESTWICK2_000779
PRESTWICK3_000779
IDI1_000953
BPBIO1_000944
SPECTRUM5_001427
DB04828
NCGC00094811-02
NCGC00094811-01
zomepirac [inn:ban]
zomepiracum [inn-latin]
einecs 251-474-2
KBIO2_000786
KBIO2_005922
KBIOGR_000905
KBIOSS_000786
KBIO3_001538
KBIO2_003354
SPECTRUM2_000955
PRESTWICK0_000779
SPECTRUM3_000589
PRESTWICK1_000779
SPBIO_002797
SPECTRUM4_000383
NINDS_000953
SPBIO_000950
SPECTRUM1500615
BSPBIO_000858
NCGC00094811-03
HMS2092E04
CHEMBL19490 ,
HMS502P15
HMS1921K11
2-[5-(4-chlorobenzoyl)-1,4-dimethylpyrrol-2-yl]acetic acid
bdbm50027952
NCGC00094811-04
pharmakon1600-01500615
nsc757379
CCG-39056
unii-822g987u9j
822g987u9j ,
zomepiracum
zom ,
1h-pyrrole-2-aceticacid, 5-(4-chlorobenzoyl)-1,4-dimethyl-
zomepirac [who-dd]
zomepirac [mi]
zomepirac [inn]
SCHEMBL25735
5-(rho-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetic acid
5-(p-chlorobenzoyl)-1,4-dimethylpyrrole-2-acetic acid
5-(p-chlorobenzoyl)-1,4-dimethyl-pyrrole-2-acetic acid
1h-pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-
AB00052126_03
DTXSID9023754
sr-05000001739
SR-05000001739-1
SBI-0051557.P002
Q4024685
FT-0708860
zomepirac; aif; ce0; ms2dec
1,4-dimethyl-5-p-chlorobenzoylpyrrole-2-acetic acid

Research Excerpts

Overview

Zomepirac sodium is a new oral analgesic that is more effective than aspirin, with no apparent tolerance or potential for addiction. It is a prostaglandin synthetase inhibitor and is not an opioid, an opioid antagonist, or a salicylate.

ExcerptReferenceRelevance
"Zomepirac sodium (ZS) is an orally active, nonnarcotic, analgesic agent. "( The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man.
Grindel, JM; McKown, LA; Migdalof, BH; O'Neill, PJ; Schwartz, MH; Wu, WN; Yorgey, KA,
)
1.91
"Zomepirac sodium is a new nonsteroidal anti-inflammatory agent for management of mild to moderate pain. "( Zomepirac-induced renal failure.
Lacher, JW; Miller, FC; Schorr, WJ, 1983
)
3.15
"Zomepirac sodium is a nonsteroidal antiinflammatory drug with potent analgesic properties. "( Anaphylactic reaction due to zomepirac.
Levy, DB; Vasilomanolakis, EC, 1984
)
2
"Zomepirac sodium is a new oral analgesic that is more effective than aspirin, with no apparent tolerance or potential for addiction. "( Zomepirac sodium -- a new oral analgesic.
, 1981
)
3.15
"Zomepirac is a prostaglandin synthetase inhibitor and is not an opioid, an opioid antagonist, or a salicylate."( Zomepirac (Zomax, McNeil Pharmaceutical).
McLeod, DC,
)
2.3
"Zomepirac is a new nonsteroidal anti-inflammatory agent (NSAIA) approved for the treatment of mild to moderately severe pain."( Evaluation of zomepirac sodium.
McEvoy, GK, 1981
)
1.34
"Zomepirac is an analgesic which is closely related chemically to the nonsteroidal anti-inflammatory agent, tolmetin. "( Zomepirac: a review of its pharmacological properties and analgesic efficacy.
Avery, GS; Brogden, RN; Carmine, AA; Heel, RC; Morley, PA; Speight, TM, 1982
)
3.15
"Zomepirac appears to be an unexpectedly effective oral, non-opioid analgesic. "( Clinical analgesic assay of oral zomepirac and intramuscular morphine.
Heidrich, G; Houde, RW; Kaiko, RF; Rogers, A; Wallenstein, SL, 1979
)
1.98
"Zomepirac is a nonsteroidal anti-inflammatory drug recently withdrawn from use because of an unexplained high incidence of immunological reactions. "( Irreversible binding of zomepirac to plasma protein in vitro and in vivo.
Benet, LZ; McDonagh, AF; Smith, PC, 1986
)
2.02

Effects

Zomepirac sodium 100 mg has been reported to be approximately equivalent to one to two tablets of aspirin-phenacetin-caffeine (APC) with codeine 30 mg. ZomePirac has been approved by the Food and Drug Administration for marketing in the United States as an analgesic.

ExcerptReferenceRelevance
"Zomepirac has been shown to be rapidly and completely absorbed after oral administration to man. "( Review of the pharmacokinetics and metabolism of zomepirac in man and animals.
Grindel, JM; Muschek, LD, 1980
)
1.96
"Thus zomepirac, which has previously shown efficacy in single-dose studies as well as good patient acceptability and efficacy in circumstances typical of clinical practice, has been found in this study to compare favorably to aspirin in a long-term (12-week) study in 238 patients with chronic pain secondary to osteoarthritis."( Long-term safety of zomepirac: a double-blind comparison with aspirin in patients with osteoarthritis.
Andelman, SY; Cannella, JJ; Ruoff, GE,
)
0.91
"Zomepirac has recently been approved by the Food and Drug Administration for marketing in the United States as an analgesic."( Zomepirac (Zomax, McNeil Pharmaceutical).
McLeod, DC,
)
2.3
"Zomepirac sodium 100 mg has been reported to be approximately equivalent to one to two tablets of aspirin-phenacetin-caffeine (APC) with codeine 30 mg."( Evaluation of zomepirac sodium.
McEvoy, GK, 1981
)
1.34
"Zomepirac has also been studied in patients with chronic orthopaedic pain or osteoarthritic pain for up to several months, without the need for increased doses."( Zomepirac: a review of its pharmacological properties and analgesic efficacy.
Avery, GS; Brogden, RN; Carmine, AA; Heel, RC; Morley, PA; Speight, TM, 1982
)
2.43

Treatment

Treatment with zomepirac sodium (5 mg/kg, i.v.), a cyclooxygenase inhibitor, resulted in highly significant reductions in the levels of all prostanoids during the preischemic period. In zomePirac sodium-treated animals, there were also highly significant reduction in the prostanoid response to ischemia.(ABSTRACT TRUNCATED AT 250 WORDS).

ExcerptReferenceRelevance
"In zomepirac sodium-treated animals, there were also highly significant reductions in the prostanoid response to ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)"( Time course of release in vivo of PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 into the brain extracellular space after 15 min of complete global ischemia in the presence and absence of cyclooxygenase inhibition.
Stevens, MK; Yaksh, TL, 1988
)
0.79
"Treatment with zomepirac sodium (5 mg/kg, i.v.), a cyclooxygenase inhibitor, resulted in highly significant reductions in the levels of all prostanoids during the preischemic period."( Time course of release in vivo of PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 into the brain extracellular space after 15 min of complete global ischemia in the presence and absence of cyclooxygenase inhibition.
Stevens, MK; Yaksh, TL, 1988
)
0.61

Toxicity

ExcerptReferenceRelevance
" In this long-term safety study, patients treated with zomepirac had significantly fewer adverse reactions and fewer limiting adverse reactions than did patients treated with aspirin."( Long-term safety of zomepirac: a double-blind comparison with aspirin in patients with osteoarthritis.
Andelman, SY; Cannella, JJ; Ruoff, GE,
)
0.7
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" However, this group of drugs is associated with serious adverse drug reactions."( Differential involvement of mitochondrial dysfunction, cytochrome P450 activity, and active transport in the toxicity of structurally related NSAIDs.
Unlü, B; van Leeuwen, JS; Vermeulen, NP; Vos, JC, 2012
)
0.38
" Clearly, longer acyl glucuronide half-lives were observed for safe drugs compared to drugs that can cause IDT."( Toxicity of Carboxylic Acid-Containing Drugs: The Role of Acyl Migration and CoA Conjugation Investigated.
Aatsinki, SM; Hokkanen, J; Lassila, T; Mattila, S; Tolonen, A; Turpeinen, M, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
" The development of NSAIDs having safer therapeutic profile depends on the better understanding of their mechanisms, physicochemical and pharmacokinetic properties."( Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
Kumar, M; Sinha, VR; Thareja, S, 2012
)
0.38

Bioavailability

The bioavailability of zomepirac was unaffected by single or repeated doses of antacid.

ExcerptReferenceRelevance
" Assessment of Z's absolute bioavailability in monkeys (10 mg/kg, iv vs."( The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man.
Grindel, JM; McKown, LA; Migdalof, BH; O'Neill, PJ; Schwartz, MH; Wu, WN; Yorgey, KA,
)
0.47
" The bioavailability of zomepirac was unaffected by single or repeated doses of antacid."( Review of the pharmacokinetics and metabolism of zomepirac in man and animals.
Grindel, JM; Muschek, LD, 1980
)
0.82
" The drug is well absorbed when given orally."( Evaluation of zomepirac sodium.
McEvoy, GK, 1981
)
0.62
" Bioavailability of zomepirac from the 3 dosage forms was much the same."( Zomepirac kinetics in healthy males.
Gottlieb, S; Nayak, RK; Ng, KT; Plostnieks, J, 1980
)
2.03

Dosage Studied

Zomepirac (ZP) and diflunisal (DF), the hypolipidemic agent clofibric acid (CA), and the anti-epileptic agent valproic acid (VPA) was statistically better than dihydrocodeine.

ExcerptRelevanceReference
" Flurbiprofen in 50 mg and 100 mg dosages demonstrated effective analgesic activity with the 100 mg dosage being at least as effective as the acetaminophen/codeine combination."( The analgesic efficacy of flurbiprofen compared to acetaminophen with codeine.
Cooper, SA; Kupperman, A, 1991
)
0.28
" In the multiple dosing phase, zomepirac was statistically better than dihydrocodeine."( Zomepirac, dihydrocodeine and placebo compared in postoperative pain after day-case surgery. The relationship between the effects of single and multiple doses.
Bullingham, RE; Carroll, D; Collin, J; Evans, PJ; Lloyd, JW; McQuay, HJ; Moore, RA; O'Sullivan, G, 1985
)
2
" Dosage adjustments may, therefore, be necessary in patients with cirrhosis of the liver."( Abnormal glucuronidation of zomepirac in patients with cirrhosis of the liver.
Bircher, J; Huguenin, P; Preisig, R; Witassek, F,
)
0.43
" Bioavailability of zomepirac from the 3 dosage forms was much the same."( Zomepirac kinetics in healthy males.
Gottlieb, S; Nayak, RK; Ng, KT; Plostnieks, J, 1980
)
2.03
" In this study, we compared the extent and pattern of covalent adduct formation in plasma and livers of rats dosed with the nonsteroidal anti-inflammatory drugs (NSAIDs) zomepirac (ZP) and diflunisal (DF), the hypolipidemic agent clofibric acid (CA), and the anti-epileptic agent valproic acid (VPA)."( Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma.
Bailey, MJ; Dickinson, RG,
)
0.33
" ZP-modified tubulin was shown to be present in the cytosol of livers from rats dosed twice daily for 3 days with ZP at 50 mg/kg, using a sandwich ELISA with ZP and tubulin antisera."( Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system.
Bailey, MJ; de Jersey, J; Dickinson, RG; Worrall, S, 1998
)
1.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
cardiovascular drugA drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyrrolesAn azole that includes only one N atom and no other heteroatom as a part of the aromatic skeleton.
monochlorobenzenesAny member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine.
monocarboxylic acidAn oxoacid containing a single carboxy group.
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)15.00000.00051.41288.2000AID160707
Prostaglandin G/H synthase 2 Bos taurus (cattle)IC50 (µMol)15.00000.00050.57393.4000AID160707
Lactoylglutathione lyaseHomo sapiens (human)Ki259.10000.00122.59479.1400AID568008; AID568009; AID604299
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
meiotic spindle organizationProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin biosynthetic processProstaglandin G/H synthase 2 Bos taurus (cattle)
ovarian cumulus expansionProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of protein phosphorylationProstaglandin G/H synthase 2 Bos taurus (cattle)
response to oxidative stressProstaglandin G/H synthase 2 Bos taurus (cattle)
cyclooxygenase pathwayProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of embryonic developmentProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to interleukin-1Prostaglandin G/H synthase 2 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 2 Bos taurus (cattle)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
positive regulation of meiotic cell cycle process involved in oocyte maturationProstaglandin G/H synthase 2 Bos taurus (cattle)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
carbohydrate metabolic processLactoylglutathione lyaseHomo sapiens (human)
regulation of transcription by RNA polymerase IILactoylglutathione lyaseHomo sapiens (human)
glutathione metabolic processLactoylglutathione lyaseHomo sapiens (human)
methylglyoxal metabolic processLactoylglutathione lyaseHomo sapiens (human)
osteoclast differentiationLactoylglutathione lyaseHomo sapiens (human)
negative regulation of apoptotic processLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
peroxidase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 2 Bos taurus (cattle)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
lactoylglutathione lyase activityLactoylglutathione lyaseHomo sapiens (human)
protein bindingLactoylglutathione lyaseHomo sapiens (human)
zinc ion bindingLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
nuclear inner membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
nuclear outer membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
endoplasmic reticulum membraneProstaglandin G/H synthase 2 Bos taurus (cattle)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nucleoplasmLactoylglutathione lyaseHomo sapiens (human)
cytoplasmLactoylglutathione lyaseHomo sapiens (human)
cytosolLactoylglutathione lyaseHomo sapiens (human)
plasma membraneLactoylglutathione lyaseHomo sapiens (human)
extracellular exosomeLactoylglutathione lyaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID184650Chronic gastrointestinal erosive activity in rats1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-ca rboxyl ic acids and 1-methyl-4-(methylthio)-5-aroylpyrrole-2-acetic acids.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1217710Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217711Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1217704Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID677462Dissociation constant, pKa of the compound2012European journal of medicinal chemistry, Jul, Volume: 53Self-organizing molecular field analysis of NSAIDs: assessment of pharmacokinetic and physicochemical properties using 3D-QSPkR approach.
AID227554Acute therapeutic index as ratio of potency in pleural effusion to that of potency in gastric toxicity assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID188014Evaluated for acute potency in pleural effusion assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID442515Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1217727Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1217709Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID568009Inhibition of glyoxalase 12011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
AID1217729Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1217728Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID186645Evaluated for chronic intestinal toxicity (multiple oral dose) in rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID131185Compound was tested orally for its ability to induce gastric lesions in fasted mice (8-animals per group)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents.
AID624647Inhibition of AZT glucuronidation by human UGT enzymes from liver microsomes2005Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID188015Evaluated for chronic potency in adjuvant arthritis assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID178656Antiinflammatory activity was determined by inhibition of adjuvant-induced arthritis in rats with respect to naproxen; ND means no data1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids. The 6-substituted compounds.
AID1656362Half life of the compound in buffer2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Designing around Structural Alerts in Drug Discovery.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID114054Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 20 min following oral administration1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1217706Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID131184Analgesic activity tested by phenylquinone induced writhing test in mice1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1217708Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID179690Acute gastric toxicity (single oral dose) in male fasted rats1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID235599Ratio of MED GI erosion to ED30 for carrageenan rat paw was determined1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids. The 6-substituted compounds.
AID1221781Cytotoxicity against HEK293 cells expressing UGT1A4 assessed as decrease in cell viability at 0.1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1217712Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1217705Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID128488Analgesic activity was assessed from the ability to inhibit phenylquinone-induced writhing in mouse at a dose of 70 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-ca rboxyl ic acids and 1-methyl-4-(methylthio)-5-aroylpyrrole-2-acetic acids.
AID195802Antiinflammatory activity (po) against carrageenan-induced paw edema in female rats relative to phenylbutazone; Not tested1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Analgetic and antiinflammatory 7-aroylbenzofuran-5-ylacetic acids and 7-aroylbenzothiophene-5-ylacetic acids.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID176481Chronic gastrointestinal erosive activity in male rats by the oral administration was determined.1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Analgetic and antiinflammatory 7-aroylbenzofuran-5-ylacetic acids and 7-aroylbenzothiophene-5-ylacetic acids.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID183644Antiinflammatory activity was evaluated by the inhibition of rat carrageenan foot edema (CFE) assay at the dose of 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1221783Cytotoxicity against HEK293 cells expressing UGT assessed as decrease in cell viability at 0.1 mM measured up to 72 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID1217707Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID133689Analgesic activity determined by its ability to inhibit phenylbenzoquinone (PBQ, ip) induced abdominal writhing at dose of 30 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids.
AID113098Analgesic activity in mice by phenyl quinone-induced writhing assay with respect to aspirin.1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids. The 6-substituted compounds.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID442514Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID160707Inhibition of prostaglandin G/H synthase obtained from bovine seminal vesicles.1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID178659Antiinflammatory activity was determined by inhibition of cotton pellet granuloma in rats with respect to Indomethacin1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids. The 6-substituted compounds.
AID234213Therapeutic ratio of MED GI erosion to that of ED30 of rat paw1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-ca rboxyl ic acids and 1-methyl-4-(methylthio)-5-aroylpyrrole-2-acetic acids.
AID160882Ability to inhibit prostaglandin synthetase ([3H]PGE2 synthesis) from [3H]arachidonic acid in bovine seminal vesicles1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
7-Aroyl-2,3-dihydrobenzo[b]furan-3-carboxylic acids and 7-benzoyl-2,3-dihydrobenzo[b]thiophene-3-carboxylic acids as analgesic agents.
AID177016Antiinflammatory activity was determined by inhibition of carrageenan-induced edema in rat paw with respect to phenylbutazone1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids. The 6-substituted compounds.
AID243230Binding affinity towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID239780Percentage plasma protein binding towards human serum albumin2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Predicting human serum albumin affinity of interleukin-8 (CXCL8) inhibitors by 3D-QSPR approach.
AID228468Chronic therapeutic index as ratio of potency in adjuvant-induced arthritis assay to that of potency in intestinal toxicity assay1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID178658Antiinflammatory activity was determined by inhibition of cotton pellet granuloma in rats with respcet to Indomethacin; ND means no data1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acids. The 6-substituted compounds.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID114055Oral analgesic activity was determined in mice by the acetylcholine-induced abdominal constriction assay upon ip administration of acetylcholine bromide 5 hours following oral administration1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
Antiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID123810Inhibition of phenylquinone -induced writhing in male mice by p.o. administration 20 min prior to i.p. phenylquinone (relative to aspirin).1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Analgetic and antiinflammatory 7-aroylbenzofuran-5-ylacetic acids and 7-aroylbenzothiophene-5-ylacetic acids.
AID177015Antiinflammatory activity assessed by inhibition of carrageenan-induced edema in rats at a dose of 15 mg/kg1989Journal of medicinal chemistry, Jun, Volume: 32, Issue:6
Synthesis and antiinflammatory and analgesic activity of 5-aroyl-6-(methylthio)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-ca rboxyl ic acids and 1-methyl-4-(methylthio)-5-aroylpyrrole-2-acetic acids.
AID604299Inhibition of human glyoxalase 12011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I.
AID183642Antiinflammatory activity was evaluated by the inhibition of rat carrageenan foot edema (CFE) assay at the dose of 1 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1221822Cytotoxicity against HEK293 cells expressing UGT1A3 assessed as decrease in cell viability at 0.1 mM measured at 24 hrs by MTT assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes.
AID113300Dose required for the inhibition of phenylquinone-induced writhing in male mice1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Analgetic and antiinflammatory 7-aroylbenzofuran-5-ylacetic acids and 7-aroylbenzothiophene-5-ylacetic acids.
AID568008Inhibition of human recombinant His-tagged glyoxalase 1 expressed in Escherichia coli BL21 (DE3) preincubated for 20 mins by Dixon plot analysis2011Bioorganic & medicinal chemistry, Feb-01, Volume: 19, Issue:3
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (198)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990148 (74.75)18.7374
1990's14 (7.07)18.2507
2000's15 (7.58)29.6817
2010's20 (10.10)24.3611
2020's1 (0.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.07 (24.57)
Research Supply Index5.65 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index45.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials48 (20.51%)5.53%
Reviews10 (4.27%)6.00%
Case Studies38 (16.24%)4.05%
Observational0 (0.00%)0.25%
Other138 (58.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]